EU blocks $7.1bn takeover of cancer detection company

Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Exelixis takes Cipla to court over generic cancer drug

21 March 2023 Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

Asia

BGI wins $333m in DNA patent suit with Illumina

9 May 2022 Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.

Big Pharma

Illumina prevails against BGI at English High Court

21 January 2021 Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

EU blocks $7.1bn takeover of cancer detection company

More on this story

Editor's picks

Editor's picks

More features